{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:57:04Z","timestamp":1720677424776},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"S5","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After completing this course, the reader will be able to:<\/jats:p>\n                  <jats:p>Relate hypoxia to gene expression. Relate hypoxia to angiogenesis. Discuss the possible relationship between tissue hypoxia and metastatic potential.<\/jats:p>\n                  <jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit atCME.TheOncologist.com<\/jats:p>\n                  <jats:p>Within the past decade, clinical trials have shown that the presence of anemia can diminish the physical status, functional abilities, and overall quality of life (QOL) of cancer patients and can negatively influence the outcome of their treatment. However, recent preclinical and clinical studies have also shown that increasing hemoglobin levels by administering recombinant human erythropoietin (rHuEPO, epoetin alfa) may ameliorate anemia and, in doing so, improve QOL and possibly result in better treatment outcomes following radiotherapy, chemotherapy, or a combination of these modalities. Several mechanisms by which rHuEPO may improve treatment outcome have been proposed, including correction of tumor hypoxia, increased sensitivity of tumor cells to radiotherapy and chemotherapy, correction of anemia and its associated symptoms (particularly fatigue), and immune-modulated effects of rHuEPO on tumor growth. Improvement of tumor oxygenation by rHuEPO could affect treatment outcome in two ways. First, correction of hypoxia results in the downregulation of hypoxia-inducible factor 1 (HIF-1), a key regulator of cellular adaptive responses to hypoxia (e.g., angiogenesis), including many pathways that are important for tumor growth and metastasis. Interruption of the HIF-1 pathway not only limits growth of the primary tumor but also reduces the potential for the development of more aggressive tumors and metastatic spread, which could ultimately improve treatment outcome. Second, within the tumor, it is the hypoxic cells that are resistant to oxygen-dependent radiotherapy and chemotherapy, and improvement in their oxygenation would increase their sensitivity to the cytotoxic effects of such treatment.<\/jats:p>\n                  <jats:p>Correction of anemia and its associated symptoms, particularly fatigue, can have a beneficial effect on patient QOL, and this in turn may translate into greater tolerance of radiotherapy and chemotherapy, allowing patients to receive full doses and on-schedule dosing, and thus have an increased likelihood of a therapeutic response. Lastly, results of a study using a murine model of multiple myeloma have indicated that rHuEPO may induce an immune-mediated antitumor effect. Therefore, additional research is warranted to further explore the biologic actions of rHuEPO and to determine their relevance to therapeutic outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.9-90005-41","type":"journal-article","created":{"date-parts":[[2004,12,10]],"date-time":"2004-12-10T19:18:13Z","timestamp":1102706293000},"page":"41-47","source":"Crossref","is-referenced-by-count":19,"title":["rHuEPO and Improved Treatment Outcomes: Potential Modes of Action"],"prefix":"10.1093","volume":"9","author":[{"given":"Kimberly","family":"Blackwell","sequence":"first","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Gasc\u00f3n","sequence":"additional","affiliation":[{"name":"Servei d'Oncologia Medica, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Sigounas","sequence":"additional","affiliation":[{"name":"ECU Brody School of Medicine, Greenville, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Jolliffe","sequence":"additional","affiliation":[{"name":"Ortho Biotech, Raritan, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,11,1]]},"reference":[{"key":"2021122209454578900_R1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/ctrv.2000.0181","article-title":"Anaemia in cancer: pathophysiology and treatment","volume":"26","author":"Mercadante","year":"2000","journal-title":"Cancer Treat Rev"},{"issue":"suppl 8","key":"2021122209454578900_R2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0093-7754(01)90206-4","article-title":"Symptomatology of anemia","volume":"28","author":"Ludwig","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209454578900_R3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0360-3016(89)90007-2","article-title":"Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients","volume":"16","author":"Girinski","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 1","key":"2021122209454578900_R4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0167-8140(91)90184-I","article-title":"Radiotherapy and anaemia\u2014the clinical experience","volume":"20","author":"Dische","year":"1991","journal-title":"Radiother Oncol"},{"key":"2021122209454578900_R5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0167-8140(92)80126-4","article-title":"The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma","volume":"23","author":"Acht","year":"1992","journal-title":"Radiother Oncol"},{"key":"2021122209454578900_R6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0360-3016(97)00308-8","article-title":"Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx","volume":"38","author":"Tarnawski","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 4","key":"2021122209454578900_R7","first-page":"31","article-title":"The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience","volume":"174","author":"Frommhold","year":"1998","journal-title":"Strahlenther Onkol"},{"key":"2021122209454578900_R8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0360-3016(98)00348-4","article-title":"Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27","volume":"42","author":"Lee","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209454578900_R9","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1528::AID-CNCR20>3.0.CO;2-E","article-title":"The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix","volume":"86","author":"Grogan","year":"1999","journal-title":"Cancer"},{"issue":"suppl 8","key":"2021122209454578900_R10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90213-1","article-title":"The impact of hemoglobin levels on treatment outcomes in patients with cancer","volume":"28","author":"Littlewood","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122209454578900_R11","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1997.15.3.1218","article-title":"Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group","volume":"15","author":"Glaspy","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122209454578900_R12","first-page":"S122","article-title":"Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy","volume":"48","author":"Antonadou","year":"1998","journal-title":"Radiother Oncol"},{"key":"2021122209454578900_R13","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group","volume":"16","author":"Demetri","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209454578900_R14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","article-title":"Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing","volume":"19","author":"Gabrilove","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454578900_R15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0360-3016(01)01488-2","article-title":"Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx","volume":"50","author":"Glaser","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209454578900_R16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","article-title":"Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial","volume":"19","author":"Littlewood","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209454578900_R17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1634\/stemcells.20-6-485","article-title":"EPO's alter ego: erythropoietin has multiple actions","volume":"20","author":"Lappin","year":"2002","journal-title":"Stem Cells"},{"issue":"suppl 7","key":"2021122209454578900_R18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0037-1963(01)90125-8","article-title":"The negative impact of anemia on radiotherapy and chemoradiation outcomes","volume":"38","author":"Shasha","year":"2001","journal-title":"Semin Hematol"},{"key":"2021122209454578900_R19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2021122209454578900_R20","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1563-258X.2002.02032.x","article-title":"Hypoxia in breast cancer: pathogenesis, characterization and biological\/therapeutic implications","volume":"152","author":"Vaupel","year":"2002","journal-title":"Wein Med Wochenschr"},{"issue":"suppl 4","key":"2021122209454578900_R21","first-page":"24","article-title":"Clinical trial experience using erythropoietin during radiation therapy","volume":"174","author":"Lavey","year":"1998","journal-title":"Strahlenther Onkol"},{"issue":"suppl 6","key":"2021122209454578900_R22","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/0959-8049(93)91830-E","article-title":"Influence of hematocrit on tumor oxygenation and sensitivity to radiation","volume":"29A","author":"Lavey","year":"1993","journal-title":"Eur J Cancer"},{"key":"2021122209454578900_R23","first-page":"4728","article-title":"Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats","volume":"56","author":"Kelleher","year":"1996","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"2021122209454578900_R24","first-page":"20","article-title":"Can erythropoietin improve tumor oxygenation?","volume":"174","author":"Kelleher","year":"1998","journal-title":"Strahlenther Onkol"},{"issue":"suppl 4","key":"2021122209454578900_R25","first-page":"6","article-title":"Oxygenation of human tumors: the Mainz experience","volume":"174","author":"Vaupel","year":"1998","journal-title":"Strahlenther Onkol"},{"key":"2021122209454578900_R26","first-page":"7634","article-title":"Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers","volume":"63","author":"Vaupel","year":"2003","journal-title":"Cancer Res"},{"key":"2021122209454578900_R27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0360-3016(99)00384-3","article-title":"Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas","volume":"46","author":"Becker","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 1","key":"2021122209454578900_R28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0360-3016(99)90437-6","article-title":"Prognostic impact of changes in the tumor tissue pO2 during early radiotherapy in cervical cancers: improved local control in primarily hypoxic tumors with \u201creoxygenation\u201d and the impact of hemoglobin","volume":"45","author":"Strauss","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209454578900_R29","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1634\/theoncologist.7-6-492","article-title":"Impact of tumor hypoxia and anemia on radiation therapy outcomes","volume":"7","author":"Harrison","year":"2002","journal-title":"The Oncologist"},{"key":"2021122209454578900_R30","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1172\/JCI11223","article-title":"Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1","volume":"106","author":"Semenza","year":"2000","journal-title":"J Clin Invest"},{"key":"2021122209454578900_R31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jemt.10175","article-title":"Hypoxia-induced pathways in breast cancer","volume":"59","author":"Goonewardene","year":"2002","journal-title":"Microsc Res Tech"},{"key":"2021122209454578900_R32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/bjc.1998.148","article-title":"Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma","volume":"77","author":"Rofstad","year":"1998","journal-title":"Br J Cancer"},{"key":"2021122209454578900_R33","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/sj.bjc.6690586","article-title":"Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis","volume":"80","author":"Rofstad","year":"1999","journal-title":"Br J Cancer"},{"key":"2021122209454578900_R34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/095530000138259","article-title":"Microenvironment-induced cancer metastasis","volume":"76","author":"Rofstad","year":"2000","journal-title":"Int J Radiat Biol"},{"key":"2021122209454578900_R35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0959-437X(00)00193-3","article-title":"Activation of the HIF pathway in cancer","volume":"11","author":"Maxwell","year":"2001","journal-title":"Curr Opin Genet Dev"},{"key":"2021122209454578900_R36","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.94.15.8104","article-title":"Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth","volume":"94","author":"Maxwell","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209454578900_R37","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/emboj\/17.11.3005","article-title":"HIF-1 alpha is required for solid tumor formation and embryonic vascularization","volume":"17","author":"Ryan","year":"1998","journal-title":"EMBO J"},{"key":"2021122209454578900_R38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/82146","article-title":"Suppression of tumor growth through disruption of hypoxia-inducible transcription","volume":"6","author":"Kung","year":"2000","journal-title":"Nat Med"},{"key":"2021122209454578900_R39","first-page":"255","article-title":"Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200","volume":"22","author":"Giantonio","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209454578900_R40","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0360-3016(03)00012-9","article-title":"Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice","volume":"55","author":"St\u00fcben","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209454578900_R41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00066-003-1110-4","article-title":"Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation","volume":"179","author":"St\u00fcben","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"2021122209454578900_R42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s004320000215","article-title":"Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice","volume":"127","author":"St\u00fcben","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122209454578900_R43","first-page":"1358","article-title":"Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors","volume":"61","author":"Thews","year":"2001","journal-title":"Cancer Res"},{"key":"2021122209454578900_R44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/bjc.1998.572","article-title":"Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia","volume":"78","author":"Thews","year":"1998","journal-title":"Br J Cancer"},{"key":"2021122209454578900_R45","first-page":"39","volume-title":"Pathophysiology, Clinical Significance and Therapeutic Perspectives","author":"Kelleher","year":"1999"},{"key":"2021122209454578900_R46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1006\/gyno.1999.5368","article-title":"Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect","volume":"73","author":"Silver","year":"1999","journal-title":"Gynecol Oncol"},{"issue":"suppl 5","key":"2021122209454578900_R47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1634\/theoncologist.9-90005-31","article-title":"Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy","volume":"9","author":"Harrison","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209454578900_R48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(98)00115-7","article-title":"Erythropoietin for patients undergoing radiotherapy: a pilot study","volume":"50","author":"Henke","year":"1999","journal-title":"Radiother Oncol"},{"key":"2021122209454578900_R49","first-page":"99","volume-title":"Pathophysiology, Clinical Significance and Therapeutic Perspectives","author":"Lavey","year":"1999"},{"key":"2021122209454578900_R50","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(03)14567-9","article-title":"Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial","volume":"362","author":"Henke","year":"2003","journal-title":"Lancet"},{"key":"2021122209454578900_R51","first-page":"206a","article-title":"Sequential adjuvant chemo-radiotherapy with vs. without erythropoietin for patients with high-risk cervical cancer\u2014second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study","volume":"21","author":"Blohmer","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 5","key":"2021122209454578900_R52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1634\/theoncologist.9-90005-48","article-title":"rHuEPO and treatment outcomes: the preclinical experience","volume":"9","author":"Ludwig","year":"2004","journal-title":"The Oncologist"},{"issue":"suppl 5","key":"2021122209454578900_R53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1634\/theoncologist.9-90005-55","article-title":"rHuEPO and treatment outcomes: the clinical experience","volume":"9","author":"Hudis","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209454578900_R54","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJM199006143222402","article-title":"Erythropoietin treatment of anemia associated with multiple myeloma","volume":"322","author":"Ludwig","year":"1990","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2021122209454578900_R55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000204780","article-title":"Recombinant human erythropoietin in the treatment of the anaemia of cancer","volume":"87","author":"Abels","year":"1992","journal-title":"Acta Haematol"},{"key":"2021122209454578900_R56","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/1097-0142(19940515)73:10<2535::AID-CNCR2820731014>3.0.CO;2-5","article-title":"Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin","volume":"73","author":"Leitgeb","year":"1994","journal-title":"Cancer"},{"key":"2021122209454578900_R57","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.bjc.6600657","article-title":"Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy","volume":"87","author":"Fallowfield","year":"2002","journal-title":"Br J Cancer"},{"key":"2021122209454578900_R58","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1200\/JCO.2003.02.136","article-title":"Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population","volume":"21","author":"Cella","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209454578900_R59","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2021122209454578900_R60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition","volume":"5","author":"Curt","year":"2000","journal-title":"The Oncologist"},{"issue":"suppl 2","key":"2021122209454578900_R61","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition","volume":"34","author":"Vogelzang","year":"1997","journal-title":"Semin Hematol"},{"key":"2021122209454578900_R62","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2000.18.14.2695","article-title":"Cognitive function in breast cancer patients receiving adjuvant chemotherapy","volume":"18","author":"Brezden","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021122209454578900_R63","first-page":"613","article-title":"Cognitive function after systemic therapy for breast cancer","volume":"15","author":"Olin","year":"2001","journal-title":"Oncology (Huntingt)"},{"key":"2021122209454578900_R64","first-page":"S138","article-title":"Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data","volume":"76","author":"O'Shaughnessy","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"2021122209454578900_R65","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209454578900_R66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03402029","article-title":"Erythropoietin therapy for acute stroke is both safe and beneficial","volume":"8","author":"Ehrenreich","year":"2002","journal-title":"Mol Med"},{"key":"2021122209454578900_R67","first-page":"57","article-title":"Erythropoietin ameliorates chemotherapy-induced toxicity in vivo","volume":"29","author":"Sigounas","year":"2001","journal-title":"Exp Hematol"},{"key":"2021122209454578900_R68","first-page":"798a","article-title":"Erythropoietin inhibits drug-induced fibrosis and improves pulmonary function","volume":"98","author":"Sigounas","year":"2001","journal-title":"Blood"},{"key":"2021122209454578900_R69","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1600-0609.1997.tb01677.x","article-title":"Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis","volume":"58","author":"Musto","year":"1997","journal-title":"Eur J Haematol"},{"key":"2021122209454578900_R70","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.081275298","article-title":"Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models","volume":"98","author":"Mittelman","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"suppl 4","key":"2021122209454578900_R71","first-page":"4","article-title":"Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications","volume":"27","author":"Dunst","year":"2000","journal-title":"Semin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.9-90005-41","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.9-90005-41","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S5\/41\/41844371\/oncolo_9_s5_41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/9\/S5\/41\/41844371\/oncolo_9_s5_41.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:23:00Z","timestamp":1640193780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/9\/S5\/41\/6388125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,1]]},"references-count":71,"journal-issue":{"issue":"S5","published-online":{"date-parts":[[2004,11,1]]},"published-print":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.9-90005-41","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,11,1]]},"published":{"date-parts":[[2004,11,1]]}}}